These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10550477)

  • 1. Aluminum toxicity perturbs long bone calcification in the embryonic chick.
    Firling CE; Hill TA; Severson AR
    Arch Toxicol; 1999 Sep; 73(7):359-66. PubMed ID: 10550477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminum effects on blood chemistry and long bone development in the chick embryo.
    Firling CE; Severson AR; Hill TA
    Arch Toxicol; 1994; 68(9):541-7. PubMed ID: 7998819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic analysis of exposure to aluminum and an acidic condition on bone formation in young growing rats.
    Li X; Zhang L; Zhu Y; Li Y
    Environ Toxicol Pharmacol; 2011 Mar; 31(2):295-301. PubMed ID: 21787697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
    Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
    Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery.
    Minisola S; Romagnoli E; Scarnecchia L; Rosso R; Pacitti MT; Scarda A; Mazzuoli G
    Eur J Endocrinol; 1994 Jun; 130(6):587-91. PubMed ID: 8205259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration.
    Mazzaferro S; Chicca S; Pasquali M; Zaraca F; Ballanti P; Taggi F; Coen G; Cinotti GA; Carboni M
    Nephrol Dial Transplant; 2000 Jun; 15(6):877-82. PubMed ID: 10831645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations of alkaline phosphatase Ca+2-ATPase and Na+, K+-ATPase during beta-APN-induced initial bone mineralization inhibition.
    Sandhu HS; Jande SS
    Acta Anat (Basel); 1982; 112(3):242-8. PubMed ID: 6285659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
    Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
    Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
    Joffe P; Heaf JG; Jensen LT
    Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy.
    Mazzaferro S; Pasquali M; Ballanti P; Bonucci E; Costantini S; Chicca S; De Meo S; Perruzza I; Sardella D; Taggi F
    Nephrol Dial Transplant; 1995; 10(1):52-8. PubMed ID: 7724029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men.
    Gram J; Junker P; Nielsen HK; Bollerslev J
    Bone; 1998 Sep; 23(3):297-302. PubMed ID: 9737353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E; Bondatti F; Manni M; Pasquali M; Perruzza I; Sardella D; Spurio A
    Am J Nephrol; 1992; 12(4):246-51. PubMed ID: 1481872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers.
    Lems WF; Van Veen GJ; Gerrits MI; Jacobs JW; Houben HH; Van Rijn HJ; Bijlsma JW
    Br J Rheumatol; 1998 Jan; 37(1):27-33. PubMed ID: 9487247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of short-term maximal work on plasma calcium, parathyroid hormone, osteocalcin and biochemical markers of collagen metabolism.
    Kristoffersson A; Hultdin J; Holmlund I; Thorsen K; Lorentzon R
    Int J Sports Med; 1995 Apr; 16(3):145-9. PubMed ID: 7649703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thallium-induced achondroplasia in chicken embryos and the concept of critical periods during development.
    Hall BK
    Teratology; 1977 Feb; 15(1):1-15. PubMed ID: 841477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen.
    Brahm H; Ljunggren O; Larsson K; Lindh E; Ljunghall S
    Calcif Tissue Int; 1994 Dec; 55(6):412-6. PubMed ID: 7895178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents.
    Fors H; Bjarnason R; Wirént L; Albertsson-Wikland K; Bosaeust L; Bengtsson BA; Johannsson G
    Clin Endocrinol (Oxf); 2001 Nov; 55(5):617-24. PubMed ID: 11894973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.